Chemokines and their Receptors in Multiple Sclerosis

Both patient material and in vivo studies using the rodent experimental autoimmune encephalomyelitis (EAE) animal model have shown that chemokines and chemokine 

CCR2 CCL2 Presence of CCL2 in human MS lesions CCR2 mice no EAE symptoms CCL2 mice resistant to induce EAE P8A-MCP-1 inhibited clinical symptoms in EAE mice INCB3344 inhibited clinical symptoms in EAE mice 

CCRl CCL3 Presence of CCL3, CCL4 and CCL5 in human MS lesions 

CCR5 CCL4 CCL5 CCR1 mice had attenuated form of EAE CCRl antagonist BX 471 reduced EAE in rat AntiCCL3 antibody prevented onset EAE AANA -RANTES had inhibitory effect on EAE Antagonist Met-RANTES had no effect on EAE 

CXCR3 CXCL9 CXCLIO Presence of CXCL9 and CXCLIO in human MS lesions Upregulation of CXCR3 at CD4+ cells from MS patients CXCR3 mice were more susceptible to EAE CXCL10 mice were more susceptible to EAE AntiCXCLlO antibody induced exacerbation of EAE in rat AntiCXCLlO antibody decreased incidence of EAE in mice 

---